Keywords: Swedish Orphan Biovitrum, Exelixis, SOBI, Cometriq, Thyroid cancer, European commercialization
SOBI to distribute Exelixis' cancer drug Cometriq in EU
Article | 22 February 2013
US biotech firm Exelixis (Nasdaq: EXEL) has entered into a three-year with Swedish Orphan Biovitrum (STO: SOBI) to support the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.